Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Abatacept as GVHD Prophylaxis Phase 2

Complete title: Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial

Research Study Number 2692.00
Principal Investigator Leslie Kean
Phase II

Research Study Description

This is a phase II multi-center, randomized, double blind, placebo-controlled trial.

The investigators are doing this study to see if a new drug, abatacept, can be used together with a calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate to provide better protection against Acute Graft versus Host Disease (aGvHD) without causing more infections.

Funding Source - FDA OOPD

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 2692.00
Contact Brandi Bratrude
Telephone 206/884-1055

Keywords: Leukemia, Acute Lymphoblastic (ALL); Leukemia, Acute Myeloid (AML); Autoimmune Diseases; Hematologic Malignancies; Myelodysplastic Syndromes (MDS); Graft Versus Host Disease, Chronic (cGVHD); Graft Versus Host Disease (GVHD); Immune System Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials